VH 4011499
Alternative Names: GSK-4011499; VH-4011499; VH-4011499-A; VH-499Latest Information Update: 03 Oct 2024
At a glance
- Originator ViiV Healthcare
- Class Antiretrovirals
- Mechanism of Action Capsid protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II HIV infections
Most Recent Events
- 24 Jun 2024 ViiV Healthcare completes the phase II CINNAMON trial in HIV-1 infections (Treatment-naive) in USA, Argentina, Canada, France, Germany, Italy, Mexico, Spain and UK(PO) (NCT06039579) (EudraCT2023-505350-18-00)
- 17 Apr 2024 ViiV Healthcare initiates enrolment in a phase I trial for HIV infections (In volunteers) in USA (PO, Tablet) (NCT06368986)
- 16 Apr 2024 ViiV Healthcare plans a phase I trial for HIV infections (In volunteers) in April 2024 (PO, Tablet) (NCT06368986)